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The development of pulmonary edema can be considered as a combination of alveolar ﬂooding via increased ﬂuid ﬁltration,
impaired alveolar-capillary barrier integrity, and disturbed resolution due to decreased alveolar ﬂuid clearance. An important
mechanismregulatingalveolarﬂuidclearanceissodiumtransportacrossthealveolarepithelium.Transepithelialsodiumtransport
is largely dependent on the activity of sodium channels in alveolar epithelial cells. This paper describes how sodium channels
contribute to alveolar ﬂuid clearance under physiological conditions and how deregulation of sodium channel activity might
contribute to the pathogenesis of lung diseases associated with pulmonary edema. Furthermore, sodium channels as putative
molecular targets for the treatment of pulmonary edema are discussed.
1.Introduction
According to Fick’s law, the anatomy of the human lung
permits optimal gas exchange due to a large surface area and
a thin diﬀusion barrier. The large surface area is generated
by the division of airways into smaller gas exchange units
(alveoli). Alveoli consist of two cell types, alveolar type 1
(AT1) and type 2 (AT2) cells. AT1 cells are large, ﬂat cells
that build the bulk of the alveolar surface. In contrast, AT2
cells are smaller cuboidal cells, which are active secretory
cells and are responsible for the secretion of surface active
proteins and lipids, which are referred to as surfactant.
Both cell types form tight junctions and thereby build a
polar organised epithelium with an apical, “air-faced”, and a
basolateral,“blood-faced,” side. Atthebasolateralside,a thin
basal lamina separates the alveolar epithelium from the small
interstitium and the capillaries of the lung. For eﬀective gas
exchange to take place, O2 and CO2 must cross the alveolar
epithelium, the basal lamina, and the endothelial cells that
form the capillaries. Therefore, these layers are referred to
as the alveolar-capillary barrier. This barrier has a distance
of less than 1μm, a diﬀusion distance that is thin enough to
allow eﬃcient gas exchange. Thus, the anatomy of the mam-
malian lung and the structure of the alveoli satisfy Fick’s law
of diﬀusion in terms of requirements for a large surface area
andthindiﬀusiondistanceandestablishthephysicalrequire-
ments for optimal gas exchange of air breathing mammals.
Theconsequenceoftheproximityofthecapillariestothe
alveolar epithelium, however, is that small amounts of liquid
are permanently forced into the alveolar airspaces due to
blood pressure. This ﬂuid contributes to alveolar lining ﬂuid,
facilitating diﬀusion of dissolved gases such as O2 and CO2.
However, increased ﬂuid volume in the alveoli characterised
leads to an extension of the gas diﬀusion distance. Therefore,
mechanisms must exist which remove inﬁltrated ﬂuid from
the alveoli—a process referred to as alveolar ﬂuid clearance.
For this, the reabsorption of Na+ from the alveoli, especially
viatheactivityofNa+ channelsinthepulmonaryepithelium,
is of particular importance and will be discussed in further
detail below.
2. Na+ ChannelsandTheirRole inAlveolar
FluidClearance
As described above, AT1 and AT2 cells are linked together
by tight junctions. The formation of tight junctions between
these epithelial cells not only results in a tight linkage of
the cells to one another, but also limits the free diﬀusion
of transmembrane protein complexes. Thus, the protein
repertoire of the apical membrane of the alveolar epithelium
diﬀers from that of the basolateral membrane. This issue is
of particular importance for transepithelial Na+ transport,
a mechanism that is crucial for alveolar ﬂuid clearance.
Transepithelial Na+ transport occurs primarily through2 Pulmonary Medicine
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Figure 1: Transepithelial Na+ transport drives alveolar ﬂuid
clearance. Na+ enters the cell interior passively following an
electrochemical gradient via Na+ channels, which are located at the
apical membrane of alveolar epithelial cells. The Na+ ions are then
actively pumped out of the cells by the Na+/K+-ATPase in exchange
forK+ ions,whichleavethecellafterwardsviabasolaterallylocalized
potassium channels. Thus, there is a net movement of Na+ ions
from the apical (air-faced) to the basolateral (blood/interstitium-
faced) side of the alveolar epithelium. This creates osmotic forces,
and, consequently, water follows out of the airspaces across the
epitheliumeitherparacellularlyviatightjunctionsortranscellularly
via aquaporins. The ﬁgure has been modiﬁed from [2].
the interplay of two transport systems: Na+permeable ion
channels, such as the epithelial Na+ channel (ENaC), located
at the apical membrane, as well as the basolaterally localized
Na+/K+-ATPase (Figure 1). The Na+ ions enter the cells,
following an electrochemical gradient, at the apical mem-
brane via Na+ channels and are extruded at the basolateral
side by the activity of the Na+/K+-ATPase. This leads to a
net movement of Na+ from the apical to the basolateral
side of the alveolar epithelium. This transepithelial Na+
transport in turn creates osmotic forces which drive the
movement of water from the apical to the basolateral side.
Water crosses the alveolar epithelium either paracellularly
via tight junctions or transcellularly via water channels, or
aquaporins, which are expressed in alveolar type 1 cells [1].
Wateriseventuallyremovedfromthelungsviathelymphatic
or capillary system.
Thus, alveolar ﬂuid clearance is a direct consequence
of transepithelial ion and, particularly, Na+ transport
(Figure 1). This correlation was demonstrated in a study by
Hummler et al., where knock-out mice that did not express
the alpha subunit of the epithelial Na+ channel (ENaC)
in the alveolar epithelium died after birth due to defective
neonatal ﬂuid clearance and ﬂuid accumulation in the lungs
[3]. Consistent with this study, lung-speciﬁc knockdown of
αENaCusingsiRNAdecreasedbaselineﬂuidclearanceinrats
in vivo [4].
These examples underline the fact that Na+ channels in
the pulmonary epithelium play a key role in driving alveolar
ﬂuid clearance and, thus, the regulation of the ﬂuid content
of the airspaces in the lung.
3. Na+ Channelsinthe PulmonaryEpithelium
SeveraltypesofNa+ channelshavebeendescribedinalveolar
epithelial cells, including channels sensitive to the diuretic
amiloride as well as cyclic nucleotide gated cation channels
[5, 6]. Amiloride-sensitive Na+ channels in particular are
thought to represent the major pathway for apical Na+ entry
intoalveolarepithelial cells[7,8].Theircontributiontoalve-
olar ﬂuid clearance has been demonstrated in studies, which
show that amiloride is able to block active Na+ transport and
ﬂuid clearance in isolated lung models [9–13]a n din vivo
in animal studies. This ﬁnding was recently conﬁrmed by
using genetically engineered mice with mutations conferring
hypo- or hyperactivity of the amiloride-sensitive epithelial
sodium channel (ENaC). Those studies demonstrated that
the ﬂuid content of the lungs is highly dependent on the
activity of amiloride-sensitive Na+ channels, thus illustrating
the major contribution of these channels to alveolar ﬂuid
clearance [14–16].
Two distinct types of amiloride-sensitive Na+ channels
have been described in alveolar epithelial cells: highly selec-
tive Na+ channels (HSCs), which are characterized by a high
selectivity towards Na+, and nonselective cation channels
(NSCs), with no selectivity for Na+ over K+ [5, 6, 17–19].
The HSCs are also referred to as “epithelial Na+ channel
(ENaC)-like” Na+ channels [20]. The classical ENaC consists
of three subunits, α, β and γ[21], which might assemble as a
heterotrimertobuildaNa+-permeablechannelspanning the
cell membrane [22]. When these three subunits of ENaC are
coexpressedinXenopus laevis oocytes,theresultingexpressed
channel has almost identical characteristics to the HSCs
identiﬁed from lung cells [18, 23, 24]. Therefore, the HSC
observed in lung epithelia might be ENaC consisting of the
α, β and γ subunits [6, 18, 25, 26]. In contrast to the HSCs,
the structure and subunit composition of NSCs are still not
completely understood [19, 20]. It is speculated that NSCs
might solely be formed by the α subunit of ENaC [27].
In order to clarify these topics, it is important to identify
the precise structure and subunit stoichiometry in which
the classical ENaC subunits might assemble to form either
selective or nonselective ion channels. In this regard, it is
also noteworthy that an additional subunit of ENaC (δ)
has been described in humans [28] which has at least two
functionally diﬀerent splice isoforms [29, 30] that are also
expressed in the human lung (unpublished observations)
and lung epithelial cells [31, 32]. The δ subunit of ENaC
can replace the α subunit, forming Na+ channels together
with β and γ subunits when heterologously expressed in
Xenopus laevis oocytes [28]. Interestingly, these channels
have diﬀerent biophysical properties when compared to
channels containing the α subunit [31]. To what extent,
the δ ENaC subunits might be involved in, for example,
forming NSCs and how these subunits might play a role
in amiloride-sensitive pulmonary transepithelial Na+ trans-
port and alveolar ﬂuid clearance however, remain to be
elucidated.
It should be mentioned that there is also a fraction of
active Na+ transport and alveolar ﬂuid clearance which is
insensitive to amiloride [33]. However, which Na+ channelsPulmonary Medicine 3
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Figure 2: Impaired Na+ channel activity is associated with the development of pulmonary edema. (a) under normal conditions
transepithelial Na+ transport mediated via Na+ channels in the alveolar epithelium drives water reabsorption from the airspaces to the
interstitium. This mechanism counteracts water ﬁltration into the airspaces and keeps the ﬂuid layer covering the alveolar epithelium low.
(b) a variety of factors that inhibit Na+ channels in the alveolar epithelium have been identiﬁed under diseases associated with pulmonary
edema such as HAPE or ALI/ARDS: hypoxia, inﬂammatory mediators which are released by activated immune cells (such as macrophages
or neutrophils), endothelin 1 (ET-1), reactive species such as nitric oxide (NO), or factors which are released due to hypoxia or epithelial
stress such as serotonin (5-HT). The decreased activity of Na+ channels leads to decreased water reabsorption and ﬂuid accumulation in the
airspaces. Under pathological conditions such as HAPE or ALI/ARDS, there is additionally increased ﬂuid ﬁltration into the airspaces due
to impaired epithelial barrier integrity. The consequence of both impaired Na+ and thus water reabsorption and increased ﬂuid ﬁltration
is the development of pulmonary edema. The ﬁgure has been modiﬁed from [2]. For clarity, aquaporins and potassium ﬂuxes/channels, as
indicated in Figure 1, have been omitted.
or Na+-coupled transporters are involved in amiloride-
insensitive transport across the alveolar epithelium remains
unknown (for detailed review see [33]).
Aside from the identiﬁcation of the precise structure
and composition of Na+ channels in the distal lung, an
important aspect is the question as to where in the distal
lung these channels are expressed. As described earlier, the
alveolar epithelium consists of two cell types: AT1 and AT2
cells. Although AT1 cells represent less than 10% of the
cells in the lung, they form more than 98% of the lung
surface area [1]. In this regard, the classical paradigm was
thatAT1cellsare“biologicallyinert”cellsthatjustcontribute
tothethinalveolar-capillarybarrierwhereasthe“biologically
active” cells are AT2 cells [1]. Following that paradigm,
until recently, the general view was that transepithelial Na+
absorption takes place solely by AT2 cells. However, given
that AT2 cells correspond to less than 2% of the total lung
surfacearea,itseemssurprising thatthesecellsalonemanage
to drive alveolar ﬂuid clearance by transepithelial Na+-
transport. The idea of AT2 cells as the Na+ transporting cell
in the distal lung is largely rooted in the fact that these cells
have been experimentally approachable for more than 30
years [34]andhavebeenintensively investigated. Incontrast,
techniques to isolate and investigate pure populations of AT1
cells have only recently been developed [1, 35, 36]. Since
then, there have been experimental hints that isolated AT1
cells also express Na+ channels (HSC and NSC) [8, 37, 38]. It
should be mentioned that studies with AT2 cells have shown
that the expression of Na+ channels in isolated alveolar
cells is highly sensitive to culture conditions [39], and this
makes it diﬃcult to integrate data from isolated cells into a
physiological context. However, more recent data from the
Eaton group delivered hints for the existence of HSCs and
NSCs in AT1 cells of lung slice preparations [40, 41]. Thus, it
seems that AT1 and AT2 cells both express the Na+ channel
repertoire which makes them suitable for transepithelial
Na+ transport. Therefore, the classical paradigm of pure
AT2-driven Na+ absorption changes into the view that Na+
absorption takes place across the entire alveolar epithelium
mediated by Na+ channels which are expressed both in AT1
and AT2 cells.
4. Na+ Channelsandthe Development of
Pulmonary Edema
Although many open questions remain concerning the
precise Na+ channel structure and spatial expression, the
correlation between Na+ channel activity in AT1 and AT2
cells and alveolar ﬂuid clearance implies that there may
be a link between dysregulated Na+ channel activity and
the development of pulmonary edema due to impaired
resolution of ﬂuid (Figure 2). Evidence for this assumption
comes from transgenic mice with loss-of-function muta-
tions of amiloride-sensitive HSCs [14, 16]. These studies4 Pulmonary Medicine
demonstrated that hypoactive Na+ channels in the lung not
only lead to impaired alveolar ﬂuid clearance but also are
a predisposing factor for the development of pulmonary
edema [14].
The physiological importance of this association is
evidentwhenoneconsidersthedevelopmentofhigh-altitude
pulmonary edema (HAPE). Mountaineers at high altitude
are faced with physical problems: decreased atmospheric
pressure, hypoxia, and pulmonary hypertension due to
hypoxic vasoconstriction. The lower atmospheric pressure
leads to an increased pressure gradient between the airspaces
of the lung and the body interior. Thus, the described
leakage of ﬂuid—as a result of blood pressure—is enhanced.
In addition, pulmonary blood vessels respond to hypoxia
with vasoconstriction, a mechanism that usually prevents
nonventilated alveoli from being perfused. The pulmonary
blood pressure further increases ﬂuid ﬁltration into the
lungs. In addition, there is also an impairment of barrier
integrity under HAPE which augments alveolar ﬂooding
(as reviewed in [42] ) .T h es i t u a t i o nb e c o m e se v e nm o r e
problematic, since there is also an impairment of ﬂuid
resolution due to impaired Na+-transport, and the activity
of Na+ channels in particular. This phenomenon is inter
alia due to hypoxia-induced inhibition of Na+ channels
[43, 44]. The decreased Na+ channel activity in hypoxic
lungs is likely due to hypoxia-induced Na+ channel retrieval
from the alveolar epithelial cell surface without aﬀecting
total expression of Na+ channels in the lung [45]. However,
experimental studies concerning the latter issue delivered
controversial results [45–48], which might be due to the
diﬀerent degrees of hypoxia employed in the used models.
Nevertheless, the overall eﬀect of hypoxia is an impaired
transepithelialNa+ transport,whichis—atleastinpart—due
to impaired Na+ channel activity in the alveolar epithelium.
This eventually leads to a reduction of ﬂuid reabsorption
from the alveoli and thus contributes to the development of
pulmonary edema.
Taken together, the conditions leading to HAPE demon-
strate how pulmonary edema can develop as a combi-
nation of both increased ﬂuid ﬁltration and impairment
of transepithelial Na+ transport, especially epithelial Na+
channel activity (Figure 2). In this regard, there is also
an association between transepithelial Na+ transport and
a human lung disease which is referred to as acute lung
injury (ALI) or acute respiratory distress syndrome (ARDS
[49]). Apart from pronounced inﬂammation and epithelial
damage, pulmonary edema is a hallmark of this disease
[50, 51]. The formation of pulmonary edema in ALI/ARDS
occurs due to damage to the alveolar-capillary barrier, which
leadstoﬂuidleakageintothealveoliandalsoduetodefective
alveolar ﬂuid clearance mechanisms [49]. Thus, in addition
to increased edema formation due to epithelial damage,
there is also an impairment of the resolution of edema due
to diminished alveolar ﬂuid clearance, which is dependent
on the eﬃcacy of transepithelial Na+ transport [51]. There
is a correlation between transepithelial Na+ transport and
edema clearance in ALI/ARDS patients: patients that have
a functional transepithelial Na+ transport exhibit improved
pulmonary edema resolution and have a better clinical
outcome compared to patients with defective transepithelial
Na+ transport [51].
Thus, in the described pathophysiological situations,
HAPE and ALI/ARDS, there is a link between transepithelial
Na+ transport, Na+ channels in particular, and the devel-
opment of pulmonary edema. Following that line, a variety
of factors have been identiﬁed which might account for
a decreased activity of Na+ channels under these patho-
physiological conditions (Figure 2). Increased synthesis of
nitric oxide (NO) due to, for example, upregulation of
nitric oxide synthases, has been demonstrated in ALI/ARDS
[52, 53]. Furthermore, NO decreased the activity of Na+
channels (HSC and NSC) in alveolar epithelial cells [23,
41, 54, 55]. Thus, there might be a link between the
development or persistence of edema in ALI/ARDS and NO-
mediated inhibition of Na+ channels. By contrast, defective
NO synthesis is observed under HAPE [42]. However, this
putatively beneﬁcial eﬀect with respect to Na+ channel
activity might be outweighed by exaggerated pulmonary
hypertension and thus increased ﬂuid ﬁltration into the
alveoli [42].
Another factor which might account for impaired Na+
channel activity and pulmonary edema is endothelin 1 (ET-
1). ET-1 is a vasoconstrictor which regulates pulmonary
vascular tone [56]. Increased levels of ET-1 have been
demonstrated in HAPE [57] and ALI/ARDS [58]. In addi-
tion, ET-1 inhibits epithelial Na+ channels in vitro [59]a n d
decreases alveolar ﬂuid clearance in rats [60]. Thus, ET-1
not only leads to enhanced ﬂuid ﬁltration due to pulmonary
hypertension, but might also represent a key factor that
impairs the activity of Na+ channels and thus impairs the
resolution of pulmonary edema in patients with HAPE or
ALI/ARDS.
Both examples, NO and ET-1, demonstrate how dysreg-
ulated Na+ channel activity might occur under conditions as
HAPE or ALI/ARDS. Apart from ET-1 and NO, a variety of
other factors have been identiﬁed which may also contribute
to a decreased activity of Na+ channels and hence edema
development (Figure 2): inﬂammatory mediators such as
interleukin-1beta [61] or tumor necrosis factor-alpha [62]
or factors, such as serotonin, which are released as a result
of hypoxia or epithelial stress [63].
Thus, apart from hypoxia, there are intrinsic factors
that occur in diseases associated with pulmonary edema
which might contribute to disturbed ﬂuid clearance, and
henceedemaresolution,byinterferencewithNa+ channelsin
the alveolar epithelium (Figure 2). Therefore, Na+ channels
c a nb er e g a r d e da sk e yp l a y e r sw i t hr e s p e c tt oe d e m a
formation and might be promising targets for the treatment
of pulmonary edema.
5. Na+ ChannelsasMolecularTargets for
the Treatment of Pulmonary Edema?
Thedescribedexamples,HAPEandALI/ARDS,demonstrate
that pathological situations in the lung which are associated
with pulmonary edema can be correlated with an impaired
activity of Na+ channels and transepithelial Na+ transport.
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of Na+ channelactivitywouldenhanceedemaresolutionand
improve the clinical outcome of patients with pulmonary
edema.
Experimental evidence that enhanced Na+ channel activ-
ity might indeed improve edema resolution comes from
studies using transgenic mice with hyperactive Na+ channels
[64]. These mice carry a mutation in the β-subunit of
the epithelial Na+ channel, ENaC, which leads to impaired
channel retrieval, and thus, persistence of ENaC at the cell
surface [65, 66]. This mutation is the genetic reason for
a hereditary form of hypertension referred to as Liddle’s
syndrome [67]. Consistent with the association of Na+
channel activity and alveolar ﬂuid clearance, baseline ﬂuid
clearance was increased in mice carrying the β-Liddle
mutation compared to wild types [64]. Moreover, these mice
were able to resolute hydrostatic pulmonary edema (induced
by volume overload due to saline infusion) much better
than wild-type mice [64]. These results demonstrate that
increasing Na+ channel activity might be a putative tool to
potentiate alveolar ﬂuid clearance and thereby enhance the
resolution of pulmonary edema.
In this regard, β-adrenergic agonists are prominent
activators of Na+ channels in the alveolar epithelium and
therefore stimulators of alveolar ﬂuid clearance (for detailed
review see [7]). This ﬁnding has been conﬁrmed recently in
mutant mice with low expression of epithelial Na+ channels
(β-ENaC) which show no increase in alveolar ﬂuid clearance
upon β-agonist treatment [16].
Consistent with the idea of β-agonists as potential thera-
peutic tools, β-adrenergic agonist treatment improved ﬂuid
clearance and edema resolution in experimental models
of ALI/ARDS [68–71]. The activation of transepithelial
Na+ transport and alveolar ﬂuid clearance by β-adrenergic
agonists was also shown to reduce extravascular lung water
in patients who were part of the so-called BALTI trial (beta-
agonistlunginjurytrial,BALTI),aclinicaltrialthataddressed
the possibility of β-agonist treatment in ALI/ARDS [72].
Recent data also suggest that β-agonist treatment might
restore Na+ absorption and epithelial Na+ channel activity
to normal levels in hypoxic alveolar epithelial cells from rats
[73]. Consistently, β-adrenergic agonist inhalation reduced
the incidence of HAPE likely by stimulated ﬂuid absorption
[74].
Thedescribedstudieswithβ-adrenergicagonistsdemon-
strate that activation of Na+ transport, inter alia by stimulat-
ing Na+ channels, might indeed be a promising strategy to
improveedemaresolution.Thus,Na+ channelsmightindeed
represent molecular targets for the treatment of pulmonary
edema. However, it is important to note that in diseases like
HAPE or ALI/ARDS there are three steps that account for
the development of pulmonary edema: (i) alveolar ﬂooding
due to increased ﬂuid ﬁltration (ii) disturbances in the
epithelial barrier integrity, and (iii) impaired ﬂuid clearance
due to impaired transepithelial Na+ transport. Although
there are experimental studies demonstrating that edema
formation can be the result of diminished Na+ transport
despite of an intact epithelial barrier [75], especially edema
resolution driven by transepithelial Na+ transport can only
take place over an intact epithelial barrier. Barrier leakage
is beside impaired Na+ transport a characteristic of HAPE
[76]o rA L I / A R D S[ 7]. Whereas damage to the alveolar
epithelium is the major cause of barrier disruption in
patients with ALI/ARDS, it is speculated that an impairment
of barrier integrity under HAPE—independently of Na+
channel activity—might be the result of enhanced leakiness
of alveolar epithelial tight junctions [77]. Independent of
its cause, barrier damage is an important factor that has to
be carefully taken into consideration [78]. Therefore, Na+
channels cannot be the only molecular target for putative
therapeutic tools regarding the treatment of pulmonary
edema under conditions such as HAPE or ALI/ARDS.
Reducing the cause of ﬂuid ﬁltration into the alveoli and
restoring especially the epithelial barrier integrity has to be
a prerequisite for enhanced Na+ transport to be eﬀective for
edema resolution.
ThiscorrelationhasalreadybeenimplicatedintheBALTI
trial [72]. The reduction of extravascular lung water by β-
adrenergic agonist treatment was only apparent 72h after
the beginning of treatment [72]. This observation might
demonstrate that for eﬀective edema resolution to take place,
an improvement in barrier integrity is necessary. Following
that line, there are interesting data suggesting a role of β-
adrenergic agonists in stimulating barrier integrity in vitro
[79] and in patients with ALI/ARDS [80].
Therefore, future therapeutic strategies to improve
edema resolution must focus on (i) a reduction of alveolar
ﬂooding, for example, by reduction of hypoxia and pul-
monary hypertension (ii) restoration of barrier integrity and
ﬁnally (iii) enhancement of transepithelial Na+ transport,
for example, by stimulating Na+ channels in the alveolar
epithelium.
6. Concluding Remarks
Taken together, Na+ channels in alveolar epithelial cells
represent important mediators of alveolar ﬂuid clearance.
Understanding the precise structure and regulation of Na+
channels under physiological conditions in the lung as well
as their dysregulation under pathological conditions such
as HAPE or ALI/ARDS is a prerequisite for understanding
the pathogenesis of lung diseases associated with pulmonary
edema and the development of new therapeutic strategies.
It is important to point out that Na+ transport mediated
alveolar ﬂuid clearance can only take place across an intact
epithelial barrier. Thus, the challenge of future therapeutic
approaches to treat pulmonary edema will be to minimize
edema formation due to barrier damage or increased
ﬁltration and to enhance edema resolution by stimulating
Na+ transport and, particularly, Na+ channels in the alveolar
epithelium.
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